This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
October 1, 2024 – Frost & Sullivan assessed the laboratory information management systems (LIMS) industry and, based on its findings, recognizes LabVantage Solutions with the 2024 Global Company of the Year Award. SAN ANTONIO, TX. LabVantage LIMS is an enterprise platform serving the full product life cycle.
Their service offers ongoing support and development, so your digital assets continue to evolve with your business, keeping you ahead in a competitive market.
Donna LaVoie, President and CEO, will be moderating at the Biotechnology Innovation Organization (BIO) (link to page) on January 18th, between 2:00 and 3:00 pm ET.
Here are the three insights I learned this summer and what I will take back to Norway as I complete my master’s degree: The complexity of biotechnology and pharmaceuticals I think most people agree that biotechnology and pharmaceuticals are complex industries, rooted in “hard science” technology.
growth from 2023 to 2024. However, the pharma/biopharma industry overall shows stagnant R&D activity. Total R&D expenditure is approximately $276.81 billion, with a modest 2.5% This underscores the urgency to streamline drug development with newer technologies.
July 9, 2024 – Frost & Sullivan recently assessed the integrated clinical trial optimization industry and, based on its findings, recognizes Clinion with the 2024 North American Technology Innovation Leadership Award. SAN ANTONIO, TX. The company is an innovator in the clinical trial and data management space.
Looking ahead to 2024, professionals worldwide are eagerly gearing up for one of the most anticipated events in the financial calendar—the J.P. Morgan 2024 experience. As you prepare for 2024, stay informed about the latest advancements in these fields to ensure your conversations and engagements are cutting edge.
The Drug, Chemical & Associated Technologies Association (DCAT) 2024 event held in New York City on March 18-21 showcased product and technology innovations and capabilities presentations by member companies. FUJIFILM Diosynth Biotechnologies invested $1.6 The company’s acquisition of Summit Biosciences Inc.
The pharmaceutical and biotechnology industries are at the cusp of a transformative era in 2025, driven by cutting-edge innovation, evolving regulations, and increasing market pressures. Leading the charge, Novartis Pluvicto has already surpassed blockbuster sales in 2024, highlighting immense investment potential. billion in sales.
13 th February 2025 Frost & Sullivan recently analyzed the biotechnology contract research organization (CRO) industry and, based on its findings, recognizes Southern Star Research with the 2024 Asia-Pacific Competitive Strategy Leadership Award. SAN ANTONIO, TX.
November 11, 2024 – Frost & Sullivan recently assessed the multiplexed urinary tract infection detection industry and, based on its findings, recognizes PathogenDx with the 2024 North American New Product Innovation Award. SAN ANTONIO, TX.
This article explores key trends, growth opportunities, and market drivers in the cardiac biomarkers diagnostics industry from 2024 to 2029. Elabscience Biotechnology, Inc., Technological innovations, including high-sensitivity cardiac troponin assays, are significantly improving early detection and patient outcomes.
While 2024 saw a 41% decline in aggregate deal value , falling from $222 billion in 2023 to $130 billion, 2025 is poised for a rebound. The post JP Morgan Healthcare Conference 2025: Key Growth Opportunities Shaping the Future of Pharma and Biotechnology appeared first on Frost & Sullivan.
We organize all of the trending information in your field so you don't have to. Join 61,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content